Investigative Ophthalmology & Visual Science Cover Image for Volume 59, Issue 9
July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
WITHDRAWN - Electroretinography evaluation in the Göttingen Minipig: An alternative animal model for ocular preclinical safety assessment
Author Affiliations & Notes
  • Christian Li
    Study Management, CiToxLAB North America Inc., Laval, Quebec, Canada
  • Luis-Fernando Negro Silva
    Study Management, CiToxLAB North America Inc., Laval, Quebec, Canada
  • Roy Foster
    Study Management, CiToxLAB North America Inc., Laval, Quebec, Canada
  • Simon Authier
    Study Management, CiToxLAB North America Inc., Laval, Quebec, Canada
  • Footnotes
    Commercial Relationships   Christian Li, None; Luis-Fernando Negro Silva, None; Roy Foster, None; Simon Authier, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 5532. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Christian Li, Luis-Fernando Negro Silva, Roy Foster, Simon Authier; WITHDRAWN - Electroretinography evaluation in the Göttingen Minipig: An alternative animal model for ocular preclinical safety assessment. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5532.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The minipig eye shares many similarities to the human eye; making them a suitable large animal model choice in ocular toxicology testing. Electroretinography (ERG) is a common end point used to evaluate retinal toxicity following systemic exposure or ocular administration.

Methods : ERGs were recorded using an EPIC-4000 and Ganzfeld dome (LKC Technologies) following unilateral intravitreal injection into the posterior chamber at a dose volume of 100 µL. Gentamicin (5 mg/eye, n=3), indocyanine green (ICG; 0.25 mg/eye, n=4) and glycine (5 mg/eye, n=3) were used as positive controls inducing retinal toxicity, light transmission interference and neurotransmission inhibition, respectively. The contralateral eye served as an untreated control. The ERG protocol included a scotopic luminance-response curve analysis (-4.09 to 0.90 log cds/m2) and oscillatory potentials were assessed at 0.41 log cds/m2. Animals were dark-adapted prior to scotopic assessment. The photopic evaluation included a single flash followed by a 30.3 Hz flicker response at 0.41 log cds/m2. Animals were background light-adapted prior to photopic assessment.

Results : Without pharmacological treatments, scotopic b-wave amplitude and latency recorded in minipigs were comparable to other species including humans. Absolute scotopic a-wave, photopic b-wave amplitudes and oscillatory potentials in minipigs were slightly higher than dogs and rabbits. With 5 mg gentamicin, scotopic b-wave amplitudes were decreased across all light intensities (-1.59 to 0.90 log cds/m2) and with peak effects of -30.2%. Similarly, gentamicin resulted in severely decreased oscillatory potentials (mean reduction of -79.2%). Scotopic a-wave and b-wave amplitudes were generally decreased in eyes treated with 0.25 mg ICG suggesting light transmission interferences. Photopic evaluations revealed a decrease in oscillatory potentials and flicker response in eyes given 5 mg glycine and eyes given 5 mg gentamicin. Log K (retinal sensitivity) was reduced in the eyes given 5 mg gentamicin, but increased in the eyes given 5 mg glycine when compared with the contralateral control eyes.

Conclusions : The results support expected pharmacological effects following intravitreal administration and the ERG protocol evaluated here in minipigs could be considered for the assessment of retinal toxicity in preclinical toxicology studies.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×